Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide and is often refractory to chemotherapy due to the development of multidrug resistance. Lonafarnib is an orally active and potent non-peptidomimetic inhibitor of farnesyl transferase. Here, using in vitro HCC cell models, we demo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Wang, Jialiang, Lian, Yifan, Gu, Yurong, Wang, Hongbo, Gu, Lin, Huang, Yanlin, Zhou, Liang, Huang, Yuehua
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739619/
https://ncbi.nlm.nih.gov/pubmed/29285232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22086
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky